Review Article

Cell Fate and Differentiation of Bone Marrow Mesenchymal Stem Cells

Shoichiro Kokabu,1,2 Jonathan W. Lowery,3 and Eijiro Jimi1

1Division of Molecular Signaling and Biochemistry, Department of Health Improvement, Kyushu Dental University, 2-6-1 Manazuru, Kokurakita-ku, Kitakyushu, Fukuoka 803-8580, Japan
2Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Saitama Medical University, 38 Morohongo, Moroyama-machi, Iruma-gun, Saitama 350-0495, Japan
3Division of Biomedical Science, College of Osteopathic Medicine, Marian University, 3200 Cold Spring Road, Indianapolis, IN 46222, USA

Correspondence should be addressed to Shoichiro Kokabu; rl4kokabu@fa.kyu-dent.ac.jp

Received 18 March 2016; Accepted 5 May 2016

Academic Editor: Coralie Sengenes

Copyright © 2016 Shoichiro Kokabu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Osteoblasts and bone marrow adipocytes originate from bone marrow mesenchymal stem cells (BMMSCs) and there appears to be a reciprocal relationship between adipogenesis and osteoblastogenesis. Alterations in the balance between adipogenesis and osteoblastogenesis in BMMSCs wherein adipogenesis is increased relative to osteoblastogenesis are associated with decreased bone quality and quantity. Several proteins have been reported to regulate this reciprocal relationship but the exact nature of the signals regulating the balance between osteoblast and adipocyte formation within the bone marrow space remains to be determined. In this review, we focus on the role of Transducin-Like Enhancer of Split 3 (TLE3), which was recently reported to regulate the balance between osteoblast and adipocyte formation from BMMSCs. We also discuss evidence implicating canonical Wnt signalling, which plays important roles in both adipogenesis and osteoblastogenesis, in regulating TLE3 expression. Currently, there is demand for new effective therapies that target the stimulation of osteoblast differentiation to enhance bone formation. We speculate that reducing TLE3 expression or activity in BMMSCs could be a useful approach towards increasing osteoblast numbers and reducing adipogenesis in the bone marrow environment.

1. Introduction

In 2010, more than 10 million Americans over the age of 50 had osteoporosis with another 43 million Americans at risk for the disease [1]. It is estimated that greater than 1.5 million fragility fractures occur each year, with an annual health care cost of at least 14 billion US dollars [2]. By 2025, the health care expenditures for osteoporotic fractures will approach 25.3 billion US dollars [3]. Bone is constantly remodeled through the processes of bone formation by osteoblasts and bone resorption by osteoclasts. Osteoclasts are derived from hematopoietic stem cell precursors of the monocyte/macrophage lineage located in the blood and bone marrow [4]; conversely, osteoblast-lineage cells (osteoblasts and osteocytes) originate from bone marrow mesenchymal stem cells (BMMSCs) [5]. BMMSCs are a multipotent cell type that can give rise not only to osteoblast-lineage cells but also to a range of other cell types, including adipocytes [6] (Figure 1). In some pathological conditions, including senile osteoporosis, the balance between adipocyte and osteoblast differentiation is disrupted in this cell population such that adipocyte differentiation is increased relative to osteoblast differentiation and this is associated with reduced bone mass, increased bone fragility, and increased susceptibility to fracture [7]. Therefore, understanding the molecular mechanism(s) responsible for controlling the balance between osteoblastogenesis and adipogenesis in the adult bone environment is of great significance.
Table 1: The proteins regulate adipogenesis and osteoblastogenesis.

| Number | Protein(s)          | Function                        | Assay          | Reference(s) |
|--------|---------------------|---------------------------------|----------------|--------------|
| 1      | Msx2                | Adipogenesis↓; osteoblastogenesis↑ | In vitro       | [66]         |
| 2      | Dlk1/Pref-1         | Adipogenesis↓; osteoblastogenesis↑ | In vitro       | [67]         |
| 3      | TAZ                 | Adipogenesis↓; osteoblastogenesis↑ | Zebrafish; in vitro | [68]         |
| 4      | Wnt10b              | Adipogenesis↓; osteoblastogenesis↑ | Knockout mice; transgenic mice | [69]         |
| 5      | LIP                 | Adipogenesis↓; osteoblastogenesis↑ | In vitro       | [70]         |
| 6      | Decl                | Adipogenesis↓; osteoblastogenesis↑ | In vitro       | [71]         |
| 7      | Hemooxygenase-1     | Adipogenesis↓; osteoblastogenesis↑ | In vitro       | [72]         |
| 8      | ID4                 | Adipogenesis↓; osteoblastogenesis↑ | Knockout mice  | [73]         |
| 9      | Maf                 | Adipogenesis↓; osteoblastogenesis↑ | Knockout mice  | [74]         |
| 10     | Pkd1                | Adipogenesis↓; osteoblastogenesis↑ | Knockout mice  | [75]         |
| 11     | sFRP-1              | Adipogenesis↓; osteoblastogenesis↑ | In vitro       | [76]         |
| 12     | ZFP467              | Adipogenesis↓; osteoblastogenesis↑ | In vivo injection | [77]         |
| 13     | GIT2                | Adipogenesis↓; osteoblastogenesis↑ | Knockout mice  | [78]         |
| 14     | Wnt6                | Adipogenesis↓; osteoblastogenesis↑ | In vitro       | [79]         |
| 15     | Wnt10a              | Adipogenesis↓; osteoblastogenesis↑ | In vitro       | [79]         |
| 16     | VEGF                | Adipogenesis↓; osteoblastogenesis↑ | Knockout mice  | [80]         |
| 17     | Semaphorin 3A       | Adipogenesis↓; osteoblastogenesis↑ | Knockout mice  | [81]         |
| 18     | TLE3                | Adipogenesis↓; osteoblastogenesis↑ | In vitro       | [19]         |
| 19     | Slit2               | Adipogenesis↓; osteoblastogenesis↑ | In vitro       | [82]         |
| 20     | miTORC2             | Adipogenesis↓; osteoblastogenesis↑ | In vitro       | [83]         |
| 21     | Adiponectin         | Adipogenesis↓; osteoblastogenesis↑ | Knockout mice  | [84]         |
| 22     | Cysteinedioxygenase type 1 | Adipogenesis↓; osteoblastogenesis↑ | In vitro       | [85, 86]     |
| 23     | MYSM1               | Adipogenesis↓; osteoblastogenesis↑ | Knockout mice  | [87]         |

Figure 1: Bone marrow mesenchymal stem cells differentiate into both adipocytes and osteoblasts. Osteoblast and marrow adipocytes are derived from common progenitors, the bone marrow mesenchymal stem cells. BMMSCs: bone marrow mesenchymal stem cells; OBs: osteoblasts; ADs: adipocytes.

In this review, we will summarize the processes of osteoblast and adipocyte differentiation from BMMSCs, focusing on the role of Transducin-Like Enhancer of Split 3 (TLE3), which was recently reported to regulate osteoblastogenesis and adipogenesis. We also discuss the prospect of bone regenerative therapy by using stem cells.

2. Relationship between Adipogenesis and Osteoblastogenesis

Adipogenesis is driven by a complex and well-orchestrated signalling cascade composed of several key transcription factors, most notably proliferator-activated receptor-γ (PPAR-γ) and several members of the CCAAT/enhancer-binding family of proteins (C/EBPs) [8]. PPAR-γ is commonly referred to as the master regulator of adipogenesis because no factor has yet been identified that can induce normal adipogenesis in its absence [9].

BMP-SMAD signalling plays an important role in osteoblastogenesis by inducing expression of several critical transcription factors such as RUNX2, Osterix, DLX2, and DLX5 [10–12]. RUNX2 is essential for the commitment of mesenchymal stem cells to the osteoblast lineage and homozygous deletion of Runx2 in mice results in a complete lack of osteoblasts [13, 14]. It appears that adequate RUNX2 is also dosage-dependent since haploinsufficiency of Runx2 in mice or RUNX2 in humans causes hypoplastic clavicles and delayed closure of the fontanelles, defects that are characteristic of cleidocranial dysplasia in humans [15, 16]. RUNX2 controls osteoblast-related genes such as Osterix, collagen I, and osteocalcin [17] and autoregulates the Runx2 gene itself [18].

Several proteins have been reported to regulate both adipogenesis and osteoblastogenesis (Table 1) and, in general, adipogenesis is reciprocally related to osteoblastogenesis in...
BMMSCs. However, the exact nature of the signals regulating the balance between osteoblast and adipocyte formation within the bone marrow space remains to be determined. In the sections below, we seek to bring attention to TLE3, which is a relatively understudied regulator of osteoblastogenesis and adipogenesis that is a member of the Groucho/TLE family of transcription factors [19].

3. Groucho/TLE Family Member

Groucho (Gro)/Transducin-Like Enhancer of Split (TLE) family members are transcriptional cofactors in metazoans that play critical roles during development and cell fate determination, including differentiation into fat and bone cells. The names “Gro” and “TLE” are used interchangeably in the literature and in sequence databases [20] and the Drosophila genome encodes a single Gro while the mouse and human genomes encode four members of each family [21].

Groucho/TLE proteins consist of a five-domain structure [22]: a highly conserved Q domain, which is a glutamine-rich region predicted to form two coiled-coil motifs that facilitates oligomerization of Gro/TLE molecules in vitro [23–25]; a glycine/proline rich (GP) domain, which is essential for interaction of Groucho/TLE proteins with histone deacetylases (HDACs) [23, 24, 26, 27]; a CcN domain, which contains a nuclear localization sequence and putative cdc2 and casein kinase II (protein kinase CK2) phosphorylation sites; a serine/proline rich (SP) domain, which is a region rich in serine/proline residues [22, 28–30]; and a highly conserved WD40 domain, which contains multiple tryptophan and aspartic acid tandem repeats, has been shown by X-ray crystallography to form a β-propeller, and binds many kinds of transcriptional factors [20, 31].

Groucho/TLE proteins do not bind DNA directly but are instead recruited by other transcription factors and are largely considered transcriptional corepressors since they often reduce the activity of a target transcriptional factor. However, the Groucho/TLE family member TLE3 was recently reported to induce the transcriptional activity of PPAR-γ, which is a master transcriptional regulator of adipogenesis [32], suggesting that the Groucho/TLE family may act as corepressors or coactivators in a context-dependent manner.

4. Distribution of TLE3 during Development

During development, TLE3 is expressed in the placenta [33] and homozygous null Tle3 mutant mice are smaller than their heterozygous and wild type littermates. Most homozygous null Tle3 mutant embryos demonstrate severe placental defects and die in utero [34]. TLE3 is also expressed in the developing nervous system where as the neural tube closes, its distribution shifts from the entire width of the neural plate to the dorsal region and ventricular zone; expression in the roof of the mesencephalon and metencephalon remains most pronounced at this stage. TLE3 is also expressed in the dorsal root ganglia and its expression in the newly formed somites becomes restricted to a dorsal, bracket-shaped group of cells corresponding to the dermamyotome [35].

In older mouse embryos expression of TLE3 in the central nervous system (CNS) is observed along the entire length of the brain and spinal cord in the ventricular zone, with the strongest expression in the layer of cells immediately lining the lumen. In the developing eye, TLE3 is located in the lens and the neural layer of the retina. Somatic expression of TLE3 continues in the dermamyotome and in the condensing sclerote, forming the vertebrae and bones. Faint staining for TLE3 is also observed in the metanephros (embryonic kidney); tissues derived from the pharynx, including Rathke's pouch and the thymic primordial; the lining of the gut and tissues derived from the gut endoderm such as the epithelial walls of the bronchi of the lungs and the liver; and derivatives of the branchial arches such as the dorsum and intrinsic muscles of the tongue and the dental laminae of the tooth primordium [35].

In later stages of mouse development (16.5 days after conception), TLE3 expression is more restricted than at midgestation. For instance, Tle3 mRNA is detected in the ventricular zone and the cortical plate of the cerebral cortex; the colliculus; the cerebellum; the olfactory lobe; nasal epithelia; whisker follicles primordia; epithelial cells of the salivary glands; basal layer of skin and hair follicles; and derivatives of the pharyngeal pouches including the lining of the cochlea, eustachian tube, esophagus, larynx, epiglottis, and the thymus [35]. TLE3 is also expressed by cells of the bone marrow [19] and brown and white adipose tissue [32], with the expression level of TLE3 increasing with adipocyte differentiation [19, 32].

5. TLE3 Enhances Adipocyte Differentiation and Suppresses Osteoblastogenesis

Adipocytes are classically classified into two kinds: white adipocytes and brown adipocytes. White adipocytes are optimized to store energy as triglycerides in large, unilocular lipid droplets. When metabolic needs arise, white adipocytes mobilize energy through hydrolysis of triglycerides and release of free fatty acids into the circulation [36]. White adipocytes express a battery of genes involved in lipid handling, triglyceride biosynthesis, triglyceride mobilization, and endocrine signalling [37–39].

Brown adipocytes derive their color from their high mitochondrial content. Unlike white adipocytes, brown adipocytes store energy primarily to provide an intracellular fuel source for thermogenesis [40]. During cold exposure, brown adipose tissue (BAT) executes a transcriptional program that promotes energy expenditure and thermogenesis. Induction of the gene encoding Mitochondrial Uncoupling Protein-1 (UCP1) is critical for brown fat thermogenesis [41, 42]. It has been thought that Ucp1 expression is restricted to BAT; however, recent studies have demonstrated that Ucp1-positive cells can be detected even in white adipose tissue under certain circumstances. These cells are called “beige adipocytes” [43] and have characteristics of both white and brown adipose cells: during basal state, beige adipocytes
display unilocular morphology similar to white adipocytes, but upon cold stimulation, these cells acquire features of intermediate morphology ultimately resulting in expression of proteins typical for BAT and transformation of stored fat into the small lipid droplets typical for brown adipocytes [44–46].

While the transcriptional determinants of the white and brown adipocyte gene programs are incompletely understood, it is known that PPARγ is the master transcriptional regulator of both white and brown fat differentiation. In support of this, mice deficient in PPARγ lack both types of adipose tissue [9, 47–49]. Villanueva et al. [32] identified TLE3 as a cofactor for PPARγ and it was later confirmed that TLE3 enhances transcriptional activity of PPARγ, thereby inducing adipocyte differentiation of BMMSCs [19, 21]. Additionally, TLE3 disrupts the physical interaction between transcriptional cofactor PRDM16, which was identified as a key factor driving brown adipocyte lineage development [43, 50], and PPARγ, thereby suppressing brown-fat-specific genes and inducing white-fat-specific genes; the net result of these effects is impaired fatty acid oxidation and thermogenesis [51]. We predict that TLE3 has some influence on beige adipocyte formation, but further studies are needed to examine this possibility.

Described above, osteoblast-lineage cells and marrow adipocytes are derived from a common progenitor, the BMMSCs. RUNX2 controls osteoblast-related genes and is essential for commitment to the osteoblast lineage [13, 14, 52]. RUNX2 interacts with Groucho/TLE family members, which act as corepressors of RUNX2 activity [53, 54]. For instance, TLE1 and TLE2 repress RUNX2-dependent activation of osteocalcin gene transcription [55]. And TLE3 suppresses BMP2-induced osteoblast differentiation of BMMSCs via recruiting HDAC and repressing RUNX2 transcriptional activity [19].

6. Expression of TLE3 Is Regulated by Canonical Wnt Signalling

The Wnt family of nineteen secreted glycoproteins has a critical role in regulating embryonic development, cell differentiation, and cell fate determination [56]. Wnts transduce two types of intracellular signalling referred to as canonical and noncanonical pathways. Canonical Wnt signalling, that is, signalling mediated by the effector β-catenin, has a key role in adult skeletal homeostasis and bone remodeling [57] by promoting differentiation and maturation of osteoblasts and, thereby, increasing bone formation [58]. In contrast, canonical Wnt signalling suppresses adipocyte differentiation [59].

Groucho/TLE family members, including TLE3, act as transcriptional corepressors of canonical Wnt signalling via binding to the downstream effectors TCF/LEF and inhibiting Wnt target gene transcription [20, 60–62]. According to Daniels and Weis [62], β-catenin that enters the nucleus upon activation of the Wnt pathway directly competes with Groucho/TLE proteins for TCF/LEF binding to accomplish gene regulation.

Recently, Wnt responsive elements in the TLE3 promoter region were identified through comparative genomic analysis and functional analyses confirmed that expression of TLE3 is increased by Wnt signalling [21]. Given the opposing roles of TLE3 and Wnt signalling in BMMSCs differentiation, this finding suggests that induction of TLE3 by Wnt signalling is part of a negative feedback loop active during osteoblast differentiation and/or a part of a positive feedback loop during adipogenesis, suggesting that TLE3 regulates the cell fate of BMMSCs between osteoblasts and adipocytes (Figure 2).

7. Prospects for Therapy

Osteoporosis, which is one of the most abundant bone-related diseases, is characterized by low bone mass and microarchitectural deterioration of bone tissue that results in increased bone fragility and susceptibility to fracture [7]. The most commonly prescribed therapeutics are antiresorptives, such as calcitonin, estrogen, and bisphosphonates, that block osteoclast activity as a means to stabilize bone architecture. While efficacious in halting further bone loss, little or no new bone mass is added to the skeleton while on antiresorptive therapy. Recent data on the importance of continuous bone remodeling suggest that overuse of antiresorptives could lead to BRONJ [bisphosphate-related osteonecrosis of the jaw] [63] and fracture in some patients [64]. Thus, development of new, effective therapies that target enhancing bone formation by stimulating osteoblast differentiation is required.
8. Conclusion

In this review we summarized the cell fate determination and the differentiation of BM-MSCs and especially focus on the role of TLE3, which represses osteoblast differentiation and enhances adipocyte formation from BM-MSCs. Therefore, we speculate that reducing TLE3 expression or activity in BM-MSCs could be a useful approach towards increasing osteoblast numbers and reducing adipogenesis in the bone marrow environment. Recently, a delivery system involving dioleoyl trimethylammonium propane- (DOTAP-) based cationic liposomes attached to six repetitive sequences of aspartate, serine, and serine ((AspSerSer)₆) was utilized to deliver siRNAs specifically to bone formation surfaces [65]. Delivery of siRNAs against Tle3 with this delivery system might be useful for reducing mRNA levels of TLE3 in bone without affecting other organs and/or tissues. Thus, developing effective methods of reducing TLE3 expression or activity in bone locally may shed light on novel bone formation therapies.

Competing Interests

The authors declare that they have no competing interests.

Acknowledgments

The authors thank the members of the Division of Molecular Signaling and Biochemistry Department of Health Promotion, Kyushu Dental University, the Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Saitama Medical University, the Division of Pathophysiology, Research Center for Genomic Medicine, Saitama Medical University, and the Harvard School of Dental Medicine for their valuable comments and discussion.

References

[1] N. C. Wright, A. C. Looker, K. G. Saag et al., “The recent prevalence of osteoporosis and low bone mass in the united states based on bone mineral density at the femoral neck or lumbar spine,” *Journal of Bone and Mineral Research*, vol. 29, no. 1, pp. 2520–2526, 2014.

[2] S. W. Blume and J. R. Curtis, “Medical costs of osteoporosis in the elderly Medicare population,” *Osteoporosis International*, vol. 22, no. 6, pp. 1835–1844, 2011.

[3] L. G. Raisz, A. L. Elderkin, L. Schargorodski et al., “A call to action: developing and implementing a national action plan to improve bone health,” *Osteoporosis International*, vol. 20, no. 11, pp. 1805–1806, 2009.

[4] S. I. Tietelbaum, “Bone resorption by osteoclasts,” *Science*, vol. 289, no. 5484, pp. 1504–1508, 2000.

[5] M. Owen, “Marrow stromal stem cells,” *Journal of Cell Science*, no. 10, pp. 63–76, 1988.

[6] G. Chamberlaine, J. Fox, B. Ashton, and J. Middleton, “Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing,” *STEM CELLS*, vol. 25, no. 11, pp. 2739–2749, 2007.

[7] N. Harvey, E. Dennison, and C. Cooper, “Osteoporosis: impact on health and economics,” *Nature Reviews Rheumatology*, vol. 6, no. 2, pp. 99–105, 2010.

[8] E. D. Rosen, C. J. Walkey, P. Puigserver, and B. M. Spiegelman, “Transcriptional regulation of adipogenesis,” *Genes and Development*, vol. 14, no. 11, pp. 1293–1307, 2000.

[9] P. Tontonoz, E. Hu, and B. M. Spiegelman, “Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor,” *Cell*, vol. 79, no. 7, pp. 1147–1156, 1994.

[10] S. C. Xu, M. A. Harris, J. L. R. Rubenstein, G. R. Mundy, and S. E. Harris, “Bone morphogenetic protein-2 (BMP-2) signaling to the Col2a1 gene in chondroblasts requires the homeobox gene Dlx-2,” *DNA and Cell Biology*, vol. 20, no. 6, pp. 359–365, 2001.

[11] K. Nakashima, X. Zhou, G. Kunkel et al., “The novel zinc-finger-containing transcription factor Osterix is required for osteoblast differentiation and bone formation,” *Cell*, vol. 108, no. 1, pp. 17–29, 2002.

[12] K. Miyama, G. Yamada, T. S. Yamamoto et al., “A BMP-inducible gene, Dlx5, regulates osteoblast differentiation and mesodermal induction,” *Developmental Biology*, vol. 208, no. 1, pp. 123–133, 1999.

[13] T. Komori, H. Yagi, S. Nomura et al., “Targeted disruption of Cbfal results in a complete lack of bone formation owing to maturational arrest of osteoblasts,” *Cell*, vol. 89, no. 5, pp. 755–764, 1997.

[14] F. Otto, A. P. Thornell, T. Crompton et al., “Cbfal, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development,” *Cell*, vol. 89, no. 5, pp. 765–771, 1997.

[15] S. Mundlos, F. Otto, C. Mundlos et al., “Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia,” *Cell*, vol. 89, no. 5, pp. 773–779, 1997.

[16] B. Lee, K. Thirunavukkarasu, L. Zhou et al., “Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia,” *Nature Genetics*, vol. 16, no. 3, pp. 307–310, 1997.

[17] G. S. Stein, J. B. Lian, A. J. Van Wijnen et al., “Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression,” *Oncogene*, vol. 23, no. 24, pp. 4315–4329, 2004.

[18] H. Drissi, Q. Luc, R. Shakoori et al., “Transcriptional autoregulation of the bone related CBFA1/RUNX2 gene,” *Journal of Cellular Physiology*, vol. 184, no. 3, pp. 341–350, 2000.

[19] S. Kokubu, T. Nguyen, S. Ohte et al., “TLE3, transducing-like enhancer of split 3, suppresses osteoblast differentiation of bone marrow stromal cells,” *Biochemical and Biophysical Research Communications*, vol. 438, no. 1, pp. 205–210, 2013.

[20] B. H. Jennings and D. Ish-Horowicz, “The Groucho/TLE/Grg family of transcriptional co-repressors,” *Genome Biology*, vol. 9, no. 1, p. 205, 2008.

[21] S. Kokubu, T. Sato, S. Ohte et al., “Expression of TLE3 by bone marrow stromal cells is regulated by canonical Wnt signaling,” *FEBS Letters*, vol. 588, no. 4, pp. 614–619, 2014.

[22] S. Stifani, C. M. Blaumueller, N. J. Redhead, R. E. Hill, and S. Artavanis-Tsakonas, “Human homologs of a Drosophila Enhancer of split gene product define a novel family of nuclear proteins,” *Nature Genetics*, vol. 2, no. 2, pp. 119–127, 1992.

[23] G. Chen, P. H. Nguyen, and A. J. Courey, “A role for Groucho tetramerization in transcriptional repression,” *Molecular and Cellular Biology*, vol. 18, no. 12, pp. 7259–7268, 1998.
D. E. Metzger, M. Gasperowicz, F. Otto, J. C. Cross, G. D. Grbavec, R. Lo, Y. Liu, and S. Stifani, “Transducin-like receptor protein 1 (RL1),” *Molecular and Cellular Biology*, vol. 24, no. 10, pp. 4341–4350, 2004.

D. Grbavec, R. Lo, Y. Liu, and S. Stifani, “Transducin-like enhancer of split 2, a mammalian homologue of Drosophila Groucho, acts as a transcriptional repressor, interacts with hairy/enhancer of split proteins, and is expressed during neuronal development,” *European Journal of Biochemistry*, vol. 258, no. 2, pp. 339–349, 1998.

H. Brantjes, J. Roose, M. van de Wetering, and H. Clevers, “All Tcf HMG box transcription factors interact with Groucho-related co-repressors,” *Nucleic Acids Research*, vol. 29, no. 7, pp. 4140–1419, 2001.

H. Miyasaka, S. Okabe, K. Ishiguro, T. Uchida, and N. Hirokawa, “Interaction of the tail domain of high molecular weight subunits of neurofilaments with the COOH-terminal region of tubulin and its regulation by tau protein kinase II,” *The Journal of Biological Chemistry*, vol. 268, no. 30, pp. 22695–22702, 1993.

A. L. Fisher and M. Caudy, “Groucho proteins: transcriptional corepressors for specific subsets of DNA-binding transcription factors in vertebrates and invertebrates,” *Genes and Development*, vol. 12, no. 13, pp. 1931–1940, 1998.

S. M. Parkhurst, “Groucho: making its Marx as a transcriptional co-repressor,” *Trends in Genetics*, vol. 14, no. 4, pp. 130–132, 1998.

L. M. Pickles, S. M. Roe, E. J. Hemingway, S. Stifani, and L. H. Pearl, “Crystal structure of the C-terminal WD40 repeat domain of the human Groucho/TLE1 transcriptional corepressor,” *Structure*, vol. 10, no. 6, pp. 751–761, 2002.

C. J. Villanueva, H. Waki, C. Godio et al., “TLE3 is a dual-function transcriptional coregulator of adipogenesis,” *Cell Metabolism*, vol. 13, no. 4, pp. 413–427, 2011.

H. Nakayama, Y. Liu, S. Stifani, and J. C. Cross, “Developmental restriction of Mash-2 expression in trophectoderm correlates with potential activation of the Notch-2 pathway,” *Developmental Genetics*, vol. 21, no. 1, pp. 21–30, 1997.

D. E. Metzger, M. Gaspertowicz, F. Otto, J. C. Cross, G. Gradwohl, and K. S. Zaret, “The transcriptional co-repressor Grg3/Tle3 promotes pancreatic endocrine progenitor delamination and β-cell differentiation,” *Development*, vol. 139, no. 8, pp. 1447–1456, 2012.

C. Leon and C. G. Lobe, “Grg3, a murine groucho-related gene, is expressed in the developing nervous system and in mesenchyme-induced epithelial structures,” *Developmental Dynamics*, vol. 208, no. 1, pp. 11–24, 1997.

R. Zechner, P. C. Kienesberger, G. Haemmerle, R. Zimmermann, and A. Lass, “Adipose triglyceride lipase and the lipolytic catabolism of cellular fat stores,” *Journal of Lipid Research*, vol. 50, no. 1, pp. 3–21, 2009.

R. A. Coleman and R. M. Bell, “Selective changes in enzymes of the sn-glycerol 3-phosphate and dihydroxyacetone-phosphate pathways of triacylglycerol biosynthesis during differentiation of 3T3-L1 preadipocytes,” *Journal of Biological Chemistry*, vol. 255, no. 16, pp. 7681–7687, 1980.

K. S. Cook, H. Y. Min, D. Johnson et al., “Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve,” *Science*, vol. 237, no. 4813, pp. 402–405, 1987.

J. L. Halaas, K. S. Gajiwala, M. Maffei et al., “Weight-reducing effects of the plasma protein encoded by the obese gene,” *Science*, vol. 269, no. 5223, pp. 543–546, 1995.

R. E. Smith and J. C. Roberts, “Thermogenesis of brown adipose tissue in cold-acclimated rats,” *American Journal of Physiology*, vol. 206, pp. 143–148, 1964.

F. Bouillaud, D. Riquier, J. Thibault, and J. Weissenbach, “Molecular approach to thermogenesis in brown adipose tissue: cDNA cloning of the mitochondrial uncoupling protein,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 82, no. 2, pp. 445–448, 1985.

A. Jacobsson, U. Stadler, M. A. Glotzer, and L. P. Kozak, “Mitochondrial uncoupling protein from mouse brown fat. Molecular cloning, genetic mapping, and mRNA expression,” *The Journal of Biological Chemistry*, vol. 260, no. 30, pp. 16250–16254, 1985.

S. Kajimura, P. Seale, K. Kubota et al., “Initiation of myoblast to brown fat switch by a PRDM16-C/EBP-β transcriptional complex,” *Nature*, vol. 460, pp. 1154–1158, 2009.

A. Park, W. K. Kim, and K. H. Bae, “Distinction of white, beige and brown adipocytes derived from mesenchymal stem cells,” *World Journal of Stem Cells*, vol. 6, no. 1, pp. 33–42, 2014.

T. B. Walden, I. R. Hansen, J. A. Timmons, B. Cannon, and J. Nedergaard, “Recruited vs. nonrecruited molecular signatures of brown, “brite,” and white adipose tissues,” *American Journal of Physiology-Endocrinology and Metabolism*, vol. 302, no. 1, pp. E19–E31, 2012.

J. Wu, P. Boström, L. M. Sparks et al., “Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human,” *Cell*, vol. 150, no. 2, pp. 366–376, 2012.

Y. Barak, M. C. Nelson, E. S. Ong et al., “PPARγ is required for placental, cardiac, and adipose tissue development,” *Molecular Cell*, vol. 4, no. 4, pp. 585–595, 1999.

E. D. Rosen, P. Sarraf, A. E. Troy et al., “PPARγ is required for the differentiation of adipose tissue in vivo and in vitro,” *Molecular Cell*, vol. 4, no. 4, pp. 611–617, 1999.

P. Tontonoz, E. Hu, R. A. Graves, A. I. Budavari, and B. M. Spiegelman, “mPPARγ2: tissue-specific regulator of an adipocyte enhancer,” *Genes & Development*, vol. 8, no. 10, pp. 1224–1234, 1994.

P. Seale, B. Bjork, W. Yang et al., “PRDM16 controls a brown fat/skeletal muscle switch,” *Nature*, vol. 454, no. 7207, pp. 961–967, 2008.

C. J. Villanueva, L. Vergnes, J. Wang et al., “Adipose subtype-selective recruitment of TLE3 or prdm16 by PPARγ specifies lipid storage versus thermogenic gene programs,” *Cell Metabolism*, vol. 17, no. 3, pp. 423–435, 2013.

P. Ducy, R. Zhang, V. Geoffroy, A. L. Ridall, and G. Karsenty, “Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation,” *Cell*, vol. 89, no. 5, pp. 747–754, 1997.

J. J. Westendorf, “Transcriptional co-repressors of Runx2,” *Journal of Cellular Biochemistry*, vol. 98, no. 1, pp. 54–64, 2006.

K. W. McLaren, R. Lo, D. Grbavec, K. Thirunavukkarasu, G. Karsenty, and S. Stifani, “The mammalian basic helix loop helix protein HES-1 binds to and modulates the transactivating function of the runt-related factor Cbfα1,” *Journal of Biological Chemistry*, vol. 275, no. 1, pp. 530–538, 2000.

A. Javed, B. Guo, S. Hiebert et al., “Groucho/TLE/R-esp proteins associate with the nuclear matrix and repress RUNX (CBF(alpha)/AML/PEBP2(alpha)) dependent activation of tissue-specific gene transcription,” *Journal of Cell Science*, vol. 113, no. 12, pp. 2221–2231, 2000.
[56] R. T. Moon, B. Bowerman, M. Boutros, and N. Perrimon, “The promise and perils of Wnt signaling through β-catenin,” *Science*, vol. 296, no. 5573, pp. 1644–1646, 2002.

[57] D. G. Monroe, M. E. McGee-Lawrence, M. J. Oursler, and J. J. Westendorf, “Update on Wnt signaling in bone cell biology and bone disease,” *Gene*, vol. 492, no. 1, pp. 1–18, 2012.

[58] V. Rosen, “Harnessing the parathyroid hormone, Wnt, and bone morphogenetic protein signaling cascades for successful bone tissue engineering,” *Tissue Engineering—Part B: Reviews*, vol. 17, no. 6, pp. 475–479, 2011.

[59] S. E. Ross, N. Hemati, K. A. Longo et al., “Inhibition of adiopogenesis by Wnt signaling,” *Science*, vol. 289, no. 5481, pp. 950–953, 2000.

[60] R. A. Cavallo, R. T. Cox, M. M. Moline et al., “*Drosophila* Tcf and Groucho interact to repress wingless signalling activity,” *Nature*, vol. 395, no. 6702, pp. 604–608, 1998.

[61] J. Roose, M. Molenaar, J. Peterson et al., “The *Xenopus* Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors,” *Nature*, vol. 395, no. 6702, pp. 608–612, 1998.

[62] D. L. Daniels and W. I. Weis, “β-catenin directly displaces Groucho/LEF repressors from Tcf/LEF in Wnt-mediated transcription activation,” *Nature Structural and Molecular Biology*, vol. 12, no. 4, pp. 364–371, 2005.

[63] R. E. Marx, “Pamidronate (Aredia) and zoledronate (Zometa) through a β-catenin-independent mechanism,” *The Journal of Biological Chemistry*, vol. 286, no. 9, pp. 4186–4198, 2011.

[64] X. Zhao, P. Deng, J. Feng et al., “Cysteine dioxygenase type 1 interacts with Groucho-related transcriptional repressors,” *Nature*, vol. 395, no. 6702, pp. 604–608, 1998.

[65] B. S. Sen, Z. Xie, N. Case et al., “MTORC2 regulates mechanically induced cytoskeletal reorganization and lineage selection in marrow-derived mesenchymal stem cells,” *Journal of Bone and Mineral Research*, vol. 29, no. 1, pp. 78–89, 2014.